Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01050439
NCT01050439TerminatedPhase 2

Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders

Columbia University1 site in 1 country22 target enrollmentStarted: November 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Terminated
Enrollment
22
Locations
1
Primary Endpoint
Incidence of toxicity related to myeloablative therapy
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree of engraftment in patients with selected malignant and non malignant disorders.

Detailed Description

This is a non-randomized study to determine the tolerability and degree of engraftment of unrelated matched donor allogeneic stem cell transplantation with either myeloablative or reduced intensity conditioning in patients with selected malignant and non malignant disorders. Patients will receive one of either full intensity or reduced intensity regimen based on the patient's disease status, organ function and performance and determined by the PI.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
— to 55 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adequate renal function defined as: serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR > 40 ml/min/m2 or > 40 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range.
  • •Adequate liver function defined as: total bilirubin < 2.5 x normal; or SGOT (AST) or SGPT (ALT) < 5.0 x normal.
  • •Adequate cardiac function defined as: shortening fraction of > 25% by echocardiogram, or ejection fraction of > 40% by radionuclide angiogram or echocardiogram.
  • •Adequate pulmonary function defined as: DLCO > 35% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% in room air.
  • •Diseases:
  • •CML (CP, AP or BC)
  • •AML/MDS/JCML
  • •Lymphoma (Hodgkin's and non-Hodgkin's)
  • •Non-malignant disorders
  • •Bone Marrow Failure Syndromes: Patients with the following diagnoses are eligible:
  • •Severe Aplastic Anemia:
  • •Fanconi Anemia
  • •Severe Congenital Neutropenia (Kostmann's Syndrome)
  • •Amegakaryocytic Thrombocytopenia
  • •Diamond-Blackfan Anemia
  • •Infantile Osteopetrosis
  • •Schwachman-Diamond Syndrome
  • •Dyskeratosis Congenita
  • •Other bone marrow failure syndromes at discretion of Principal Investigator
  • •Immunodeficiencies:
  • •SCIDS, all subtypes
  • •Combined Immunodeficiency Syndrome
  • •Wiskott-Aldrich syndrome
  • •Chronic Granulomatous Disease
  • •Chediak-Higashi Syndrome
  • •Leukocyte Adhesion Deficiency
  • •Other immunodeficiencies at discretion of Principal Investigator
  • •Inborn Errors of Metabolism (IEOM):
  • •Transplant is recommended for the following disorders: Hurler syndrome (L-iduronidase deficiency, MPS-I), Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency, MP VI), Sly syndrome (glucuronidase deficiency, MPS-VII), Globoid cell Leukodystrophy (galactocerebrosidasedeficiency), Metachromatic leukodystrophy (arylsulfatase A deficiency), Childhood-onset X-linked adrenoleukodystrophy (X-ALD), Fucosidosis (fucosidase deficiency), Mannosidosis, Aspartylglucosaminuria, Niemann-Pick Disease Type B (acid sphingomyelinase deficiency), Gaucher disease (glucocerebrosidase deficiency) Type I (non neuropathic), Other diagnoses may be considered at the discretion of the Principal Investigator
  • •For X-ALD patients greater than 5 years of age, IQ > 80 is required. For other patients greater than 5 years of age, IQ > 70 is required.
  • •For patients less than 5 years of age, the developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g. mechanical ventilation) would not be predicted to be required in the year following transplantation.
  • •Histiocytosis:
  • •Hemophagocytic Lymphohistiocytosis (HLH)
  • •Familial Erythrophagocytic Lymphohistiocytosis
  • •Langerhans Cell Histiocytosis
  • •Malignant Histiocytosis
  • •Other Malignant and non-malignant diseases: Other malignant and non-malignant diseases not listed above may be eligible if deemed appropriate by the Principal Investigator.

Exclusion Criteria

  • •Women who are pregnant and/or breast feeding are ineligible

Outcomes

Primary Outcomes

Incidence of toxicity related to myeloablative therapy

Time Frame: Up to 10 years from start of study

To determine the safety and toxicity of myeloablative therapy (TBI + Melphalan) and unrelated donor alloSCT in selected patients with malignant and non-malignant disorders.

Secondary Outcomes

  • Incidence of toxicity related to reduced intensity therapy(Up to 10 years from start of study)
  • Percentage of donor chimerism(Up to 10 years from start of study)
  • Prevalence of progression free survival(Up to 10 years from start of study)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 2
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerChronic Myeloproliferative DisordersMultiple Myeloma and Plasma Cell NeoplasmLymphomaLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnusual Cancers of Childhood
NCT00281879OHSU Knight Cancer Institute200
Completed
Not Applicable
Stem Cell Transplant From Matched Unrelated or Partially Matched Related DonorsBlood CancerBlood and Marrow Transplant (BMT)
NCT00186225Stanford University250
Recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cellsMDS (Myelodysplastic Syndrome)Severe Aplastic Anemia
NCT01174108National Heart, Lung, and Blood Institute (NHLBI)120
Completed
Early Phase 1
Donor Stem Cell Transplantation for Congenital ImmunodeficienciesInherited Immune Deficiencies
NCT00426517National Institute of Allergy and Infectious Diseases (NIAID)48
Completed
Not Applicable
Unrelated Stem Cell Transplantation for Adults With Hematopoietic DisordersCMLALLMyelodysplasiaMyeloproliferative DisordersLymphomaAML
NCT00511537University of California, San Francisco30
Unrelated Donor Transplant for Malignant... | Clinical Trial